German Research Foundation

EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists

Retrieved on: 
вторник, апреля 2, 2024
Patient, MIB, ARI, Therapy, AAO, Research, Surgeon, Thomas Jefferson University, German Research Foundation, Chairperson, American Diabetes Association, Macular degeneration, SAB, FACS, Food, Cornell University, Empire, University, Castle Connolly Medical, Laborie (company), Publication, Emerita, AMD, FDA, Cochrane (organisation), Moorfields Eye Hospital, American Academy, Most, Consultant, Physician, Royal college, Diabetic retinopathy, Commander, Pharmaceutical industry

WATERTOWN, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, today announced the appointment of leading global ophthalmologists to its Scientific Advisory Board (SAB), co-chaired by Carl Regillo M.D., FACS, Chief of the Retina Service at Wills Eye Hospital and Charles Wykoff, M.D., Ph.D., Director of Research of Retina Consultants of Texas. The SAB additions include Usha Chakravarthy, M.B.B.S., Ph.D.; Allen Ho, M.D. FACS FASRS, and Frank Holz, M.D., F.E.B.O., F.A.R.V.O. These three world-renowned retinal specialists will support advancement of the Company’s global clinical strategy ahead of the anticipated initiation of its Phase 3 pivotal trials in wet age-related macular degeneration (wet AMD) in the second half of this year. Additionally, the Company announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the trade name, DURAVYUTM (vorolanib intravitreal insert) for the Company’s lead product candidate, EYP-1901.

Key Points: 
  • “The SAB’s strategic counsel, global expertise, and scientific knowledge will be incredibly valuable during this critical time in EyePoint’s growth and expansion.
  • Dr. Chakravarthy has authored or co-authored over 400 publications, and she is invited to lecture in the UK and abroad.
  • FACS FASRS is Attending Surgeon, Director of Retina Research and Co-Director of the Retina Service of Wills Eye Hospital and Professor of Ophthalmology at Thomas Jefferson University.
  • He is a Board Member of the German Ophthalmological Society, and of the Club Jules Gonin and is past president of EURETINA.

Muon g-2 doubles down with latest measurement, explores uncharted territory in search of new physics

Retrieved on: 
четверг, августа 10, 2023
Electron, Uncertainty, University, G2, Photon, Office of Inspector General, U.S. Department of Health and Human Services, DFG, National Natural Science Foundation of China, National Science Foundation, Light, Data collection, Science and Technology Facilities Council, Fermilab, Research, DOE, Primary energy, NRF, Higgs, Student, MSIP, Istituto Nazionale di Fisica Nucleare, Korea, South Korea, Physics, Standard Model, Conceptual model, German Research Foundation, Muon g-2, Physical Review Letters, Muon, Pharmaceutical industry, Management, Television, Risk management, Uranium mining, Science, Energy

The Muon g-2 collaboration describes the result in a paper that they submitted today to Physical Review Letters.

Key Points: 
  • The Muon g-2 collaboration describes the result in a paper that they submitted today to Physical Review Letters.
  • In addition to the larger data set, this latest g-2 measurement is enhanced by updates to the Fermilab experiment itself.
  • In 2020, the Muon g-2 Theory Initiative announced the best Standard Model prediction for muon g-2 available at that time.
  • Until then, physicists have a new and improved measurement of muon g-2 that is a significant step toward its final physics goal.

Keysight Enabling University of Stuttgart to Advance 6G Integrated Circuits Research

Retrieved on: 
вторник, августа 8, 2023
Technology, Mobile, Wireless, Research, Semiconductor, Software, Hardware, University, Science, Education, Hertz, Communication, University of Stuttgart Library, DFG, AWG, VDI, ICS, University of Stuttgart, VSA, VCA, VNA, Terahertz, Digital technology, German, German Research Foundation, Next Generation, NYSE, Cross-link, Cable television, Mobile phone, Keysight

Keysight Technologies, Inc. (NYSE: KEYS) is enabling the University of Stuttgart to conduct foundational research essential to development of new integrated circuits (ICs) for 6G technology with the new Keysight 6G Vector Component Analysis (VCA) solution .

Key Points: 
  • Keysight Technologies, Inc. (NYSE: KEYS) is enabling the University of Stuttgart to conduct foundational research essential to development of new integrated circuits (ICs) for 6G technology with the new Keysight 6G Vector Component Analysis (VCA) solution .
  • This is the latest collaboration from Keysight and the University of Stuttgart’s long-time research relationship.
  • The collaboration has supported the University of Stuttgart in establishing Crosslink, a versatile multiplexing platform for synchronous time- and frequency-domain analyses of ultra-broadband communication channels.
  • The Keysight and University of Stuttgart collaboration supports a large-scale equipment initiative funded by the German Research Foundation (DFG).

Amylyx Pharmaceuticals to Host Virtual Webcast on AMX0035 Progressive Supranuclear Palsy (PSP) Program

Retrieved on: 
среда, июля 12, 2023
Health, Neurology, Research, Pharmaceutical, Science, Biotechnology, DZNE, Hannover Medical School, DFG, Ludwig Maximilian University of Munich, German Center for Neurodegenerative Diseases, University, Medicine, Department of Neurology, Xuanwu hospital, Parkinson, Doctor of Philosophy, Medication, Tauopathy, LMU, Translational Neurodegeneration, Amylyx Pharmaceuticals, Physics, German, AMX0035, Neurodegenerative disease, German Research Foundation, Death, PSP, Pharmaceutical industry

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the Company will host a virtual webcast with Prof. Dr. Günter Höglinger, Director of the Department of Neurology at LMU Hospital, Ludwig-Maximilians-University (LMU) Munich, Germany, to discuss the treatment landscape for people living with progressive supranuclear palsy (PSP) and the Company’s clinical development plans for AMX0035 in PSP on July 26, 2023 at 1:30pm ET.

Key Points: 
  • Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the Company will host a virtual webcast with Prof. Dr. Günter Höglinger, Director of the Department of Neurology at LMU Hospital, Ludwig-Maximilians-University (LMU) Munich, Germany, to discuss the treatment landscape for people living with progressive supranuclear palsy (PSP) and the Company’s clinical development plans for AMX0035 in PSP on July 26, 2023 at 1:30pm ET.
  • Prof. Dr. Höglinger studied medicine and physics at the universities of Regensburg and Würzburg and earned his PhD in medicine, summa cum laude, in 2000.
  • Since 2011, he has held the Chair of the Department of Translational Neurodegeneration at the German Center for Neurodegenerative Diseases, DZNE.
  • For many years, Prof. Dr. Höglinger has been conducting translational research into tauopathies and was actively involved in many international clinical trials in PSP.

U.S. - China Trade War: Why Trump Tariffs Backfired – New EPoS Research Reveals

Retrieved on: 
вторник, июня 13, 2023
Supply Chain Management, Education, Retail, Manufacturing, Other Manufacturing, University, German Research Foundation, DFG, University of Mannheim, Electronics, Customs, Microeconomics, Green, Assistant, United States Census Bureau, Tariff, University of Mannheim Business School, Trump tariffs, Point of sale, German, Center for Economic Studies (U.S. Census Bureau), Renewable energy

In contrast, only 68 percent of China’s retaliatory tariffs were shouldered by Chinese importers, U.S. exporters paid the other 32 percent.

Key Points: 
  • In contrast, only 68 percent of China’s retaliatory tariffs were shouldered by Chinese importers, U.S. exporters paid the other 32 percent.
  • These are findings of the Discussion Paper “Who Pays for the Tariffs and Why?
  • A Tale of Two Countries” published by EPoS economic research center at the Universities of Bonn and Mannheim.
  • Access the full paper at: https://www.crctr224.de/en/research-output/discussion-papers/archive/202...
    EPoS is a cooperation of the universities Bonn and Mannheim, funded by the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG).

Government of Canada invests in high-risk, high-reward interdisciplinary research to support world-leading innovation

Retrieved on: 
вторник, апреля 25, 2023
Workforce, Natural science, The Honourable, Drinking water, Oswaldo Cruz Foundation, COVID-19, DSM-IV codes, International Development Research Centre, Social science, Public, Research, SSHRC, Natural Sciences and Engineering Research Council, Social Sciences and Humanities Research Council, Government, International development, Interdisciplinarity, TIPS, Government of Canada, First Nations, German, Artificial intelligence, German Research Foundation, Swiss National Science Foundation, Fund, Pharmaceutical industry, Renewable energy, Nursing, Science, Health

That is why the Government of Canada is there to support research teams pushing the boundaries of innovation.

Key Points: 
  • That is why the Government of Canada is there to support research teams pushing the boundaries of innovation.
  • Today, the Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, and the Honourable Jean-Yves Duclos, Minister of Health, announced more than $200 million in support for Canadian-led interdisciplinary, international, high-risk and high-reward research through the New Frontiers in Research Fund (NFRF).
  • First, the NFRF 2022 Transformation competition is funding six large-scale, interdisciplinary research projects that address major challenges.
  • Since 2016, the government has provided more than $16 billion in new resources to support science and research.

Experimental Treatment Approach Counters Allergic Asthma without Weakening Flu Defenses

Retrieved on: 
пятница, октября 7, 2022
Tao, National Institutes of Health, Medical research, NYU, New York University Grossman School of Medicine, Novo Nordisk Foundation, Science Advances, National, Icahn School of Medicine at Mount Sinai, Lung, German Research Foundation, Pathology, Virus, Feces, Infection, Inflammation, Breathe Me, Mouse, Center, Department, Mount Sinai School, Korea Disease Control and Prevention Agency, Wang, Asthma, Child, Cough, Society, Calcium, Cell, ORAI1, American Society of Hematology, Allergen, Membrane protein, St. Jude Children's Research Hospital, Immunoglobulin E, NYU Langone Health, Wheeze, Acute pancreatitis, Eosinophil, Gene expression, Experimental pathology, Disease, CRAC, Cytokine, Pain scale, MD, Doctor of Philosophy, Bernard Levin, COVID-19, Vaccine, Pharmaceutical industry, Science, T helper cell, New York University

Blocking signals sent through this channel with an investigational new drug called a CRAC channel inhibitor had a similar effect.

Key Points: 
  • Blocking signals sent through this channel with an investigational new drug called a CRAC channel inhibitor had a similar effect.
  • Allergic asthma is characterized by increased type 2 (T2) inflammation, which involves a subset of T cells called T helper (Th) 2 cells, say the study authors.
  • Without calcium entering through CRAC channels, T cells are unable to become Th2 cells and produce the cytokines that cause allergic asthma, the authors say.
  • "This suggests CRAC channel inhibition as a promising, potential future treatment approach for allergic airway disease."

Kyverna Therapeutics Names Georg Schett, M.D., and Peter A. Merkel, M.D., MPH, to Scientific Advisory Board

Retrieved on: 
вторник, августа 23, 2022
CEO, Regulation, Program, Regulatory T cell, Hospital of the University of Pennsylvania, University, Professor, Epidemiology, Internal medicine, NIH, CD19, Patient, Synthetic biology, Lupus nephritis, German Research Foundation, Scleroderma, Department, Autoimmunity, BMBF, Hospital, Yale University, Industry, MPH, Degenerative disease, CAR, Therapy, Checkpoint, Peter's Food Services, Principal, Multimedia, Internal, National academy, Coronavirus Scientific Advisory Board (Turkey), Amgen, Trustee, Collaborative Research Centres, Science, Vasculitis, National, Harvard University, Novo Nordisk Foundation, DFG, Vaccine, Pharmaceutical industry, Wood drying, Research, Rheumatology, Medicine, Arthritis, Inflammation

EMERYVILLE, Calif., Aug. 23, 2022 /PRNewswire/ -- Kyverna Therapeutics ("Kyverna"), a cell therapy company engineering a new class of therapies for serious autoimmune diseases, today announced the appointment of Georg Schett, M.D., Professor and Head of the Department of Internal Medicine 3, and Vice President of Research, Friedrich-Alexander University, Erlangen-Nürnberg, Erlangen, Germany, and Peter A. Merkel, M.D., MPH, Chief of Rheumatology and Professor of Medicine and Epidemiology at the University of Pennsylvania, as Scientific Advisors.

Key Points: 
  • "We are thrilled to have Georg and Peter, two internationally recognized experts in rheumatic and autoimmune diseases, join our Scientific Advisory Board," said Dominic Borie, M.D., Ph.D., President and CEO of Kyverna.
  • Prof. Dr. Schett's interests include basic, translational, and clinical research on molecular and cellular pathogenesis of rheumatic and autoimmune diseases.
  • Kyverna Therapeutics is a cell therapy company engineering a new class of therapies for autoimmune and inflammatory diseases.
  • By offering more than one mechanism for taming autoimmunity, Kyverna is positioned to transform how autoimmune diseases are treated.

The Center for Open Science receives the Einstein Foundation Award for Promoting Quality in Research

Retrieved on: 
среда, ноября 24, 2021
Research, University, German Research Foundation, Adoption, Center for Open Science, Movement, Openness, Social, Awareness, Solution, Society, Humanities, Center, Albert Einstein, Psychology, ELife, TOP, Transparency, Nobel Prize, OSF, RP, Knowledge, Science, COS, CB, Multimedia, Reproducibility, Bill & Melinda Gates Foundation, Pharmaceutical industry, Management

The Einstein Foundation's jury offered its official statement about the institutional award winner: "The Center for Open Science (COS) catalyzes global research culture change via a unique integrated behavior change model.

Key Points: 
  • The Einstein Foundation's jury offered its official statement about the institutional award winner: "The Center for Open Science (COS) catalyzes global research culture change via a unique integrated behavior change model.
  • "We are delighted to award the inaugural Einstein Foundation Award to Paul Ginsparg and the Center for Open Science.
  • "The awardees perfectly embody the objective of the award: to boost confidence in science by effectively promoting systematic research quality."
  • The Einstein Foundation Berlin was named German Research Foundation of the Year 2021 on the basis of its significant contribution to promoting the city as a leading international research hub.